Northern Trust Corp Has $4.35 Million Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Northern Trust Corp increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330,683 shares of the biopharmaceutical company’s stock after acquiring an additional 102,241 shares during the period. Northern Trust Corp’s holdings in Arbutus Biopharma were worth $4,351,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABUS. Vanguard Group Inc. raised its stake in shares of Arbutus Biopharma by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock worth $29,367,000 after buying an additional 62,282 shares during the last quarter. Two Seas Capital LP increased its holdings in Arbutus Biopharma by 4.2% in the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock valued at $28,583,000 after purchasing an additional 353,568 shares during the last quarter. Geode Capital Management LLC lifted its stake in Arbutus Biopharma by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company’s stock valued at $11,390,000 after buying an additional 33,536 shares during the period. BlackBarn Capital Partners LP boosted its holdings in Arbutus Biopharma by 13.1% during the fourth quarter. BlackBarn Capital Partners LP now owns 2,341,871 shares of the biopharmaceutical company’s stock worth $7,658,000 after buying an additional 270,971 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in shares of Arbutus Biopharma during the 4th quarter worth about $4,771,000. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Price Performance

NASDAQ:ABUS opened at $3.17 on Thursday. The business’s 50-day simple moving average is $3.27 and its 200-day simple moving average is $3.36. Arbutus Biopharma Co. has a fifty-two week low of $2.71 and a fifty-two week high of $4.73. The stock has a market capitalization of $607.14 million, a PE ratio of -7.37 and a beta of 1.50.

Arbutus Biopharma (NASDAQ:ABUS) last announced its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.04). Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The company had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.54 million. On average, research analysts expect that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ABUS shares. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 29th. Chardan Capital reissued a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Arbutus Biopharma has a consensus rating of “Moderate Buy” and an average target price of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.